Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MRG002

Phase 2Small molecule

SShanghai Miracogen Inc.

1

Indications

10

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction (GEJ) CancerActive, not recruiting

Gastroesophageal Junction (GEJ) CancerPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Metastatic Urothelial Cancer

NCT05754853

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Unknown status·SShanghai Miracogen Inc.·Phase 2·NCT05263869·99 enrolled

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Unknown status·SShanghai Miracogen Inc.·Phase 2/3·NCT04924699·350 enrolled

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Unknown status·SShanghai Miracogen Inc.·Phase 2·NCT04742153·66 enrolled

HER2-positive Advanced Solid Tumors1 trial

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Unknown status·SShanghai Miracogen Inc.·Phase 1·NCT04941339·74 enrolled

Biliary Tract Cancer1 trial

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Unknown status·SShanghai Miracogen Inc.·Phase 2·NCT04837508·86 enrolled

Metastatic Urothelial Cancer1 trial

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting·SShanghai Miracogen Inc.·Phase 3·NCT05754853·290 enrolled

Locally Advanced1 trial

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Unknown status·SShanghai Miracogen Inc.·Phase 2·NCT04839510·58 enrolled

3 more indications

GastroEsophageal Junction (GEJ) Cancer1 trial

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, not recruiting·SShanghai Miracogen Inc.·Phase 1/2·NCT04492488·129 enrolled

Non-Small Cell Lung Cancer1 trial

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Unknown status·SShanghai Miracogen Inc.·Phase 2·NCT05141786·100 enrolled

Gastric/Gastroesophageal Junction Cancer1 trial

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Unknown status·SShanghai Miracogen Inc.·Phase 2·NCT05141747·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for MRG002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MRG002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MRG002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Miracogen Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Miracogen Inc.

Related News